TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00661479
Drug: 100 µg Brimonidine Tartrate Implant
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 µg brimonidine tartrate implant in the study eye on Day 1.
Study: NCT01084837
Drug: velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: INDUCTIoN (Cycles 1-4)~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)~For patients wich is not planned autotransplantation, add:~Cycles 5-8~* Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~* Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)~EXTENSION TREATMENT(Cycles 9-12)~* Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22~* Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)
Study: NCT02844725
Drug: VVZ-149 injections
Normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorless, transparent liquid in water for injection
Study: NCT00675961
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
Study: NCT00922844
Drug: Sevoflurane and isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
Study: NCT01441986
Drug: Dextromethorphan hydrobromide
Normalized name: Dextromethorphan Hydrobromide
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
Study: NCT01441986
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 100 mg; tablets; single, oral dose.
Study: NCT03307174
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03228901
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of the hormone oxytocin
Study: NCT03781960
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.
Study: NCT03781960
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
Study: NCT01060566
Drug: VX-770
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
Study: NCT01060566
Drug: VX-770
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
Study: NCT00987454
Drug: Epoetin Alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40,000 IU given as subcutaneous injection weekly up to 3 doses
Study: NCT00987454
Drug: Sodium Chloride 0.9%
Normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 m/L given as subcutaneous injection weekly up to 3 doses
Study: NCT00863707
Drug: Regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT01893294
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT02831387
Drug: P-321 Ophthalmic Solution
Normalized name: p-hydroxyamphetamine / tropicamide Ophthalmic Solution [Paremyd]
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-321 Ophthalmic Solution 0.017%
Study: NCT02831387
Drug: P-321 Ophthalmic Solution placebo
Normalized name: p-hydroxyamphetamine / tropicamide Ophthalmic Solution
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match P-321 Ophthalmic Solution
Study: NCT01832285
Drug: fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/day, PO(in the mouth) each day during 6 weeks
Study: NCT03938545
Drug: RVT-1401 (Administered via subcutaneous injection)
Normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
Study: NCT00202293
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00202293
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00202293
Drug: Chlorpromazine
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000241
Drug: Flupenthixol
Normalized name: flupenthixol
DrugBank: Flupentixol (DB00875)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03468231
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Sorafenib, 400mg, Bid
Study: NCT03468231
Drug: HAIC of FOLFOX
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study: NCT03468231
Drug: HAIC of OXA
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of Oxaliplatin via the tumor feeding arteries
Study: NCT00183001
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01085266
Drug: Dimebon (latrepirdine)
Normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03187691
Drug: Oral Encochleated Amphotericin B (CAMB)
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lipid-crystal nano-particle formulation amphotericin B
Study: NCT02314182
Drug: Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.~If complications occur, emergency surgery can be performed according to the local practices of each investigator center.~Radiotherapy is allowed after randomization if indicated (MDOC).
Study: NCT02536807
Drug: Hyaluronan
Normalized name: hyaluronan
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HA gel injection
Study: NCT00799513
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
Study: NCT02630693
Drug: Palbociclib 100mg
Normalized name: PALBOCICLIB 100MG TAB
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg PO daily
Study: NCT02630693
Drug: Palbociclib 125mg
Normalized name: PALBOCICLIB 125MG TAB
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125mg PO daily 3 weeks out of 4
Study: NCT02630693
Drug: Fulvestrant or Tamoxifen or Aromatase Inhibitor
Normalized name: Medicated Pad or Tape
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given at the standard doses/schedules
Study: NCT03690232
Drug: glucose water
Normalized name: Albertsons Glucose Watermelon
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sessions of 6cc 25% glucose injection with a 2-week interval
Study: NCT03690232
Drug: hyaluronic aicd
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment
Study: NCT00748202
Drug: C1-Esterase Inhibitor
Normalized name: HUMAN C1-ESTERASE INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 1000 I.E.
Study: NCT03639168
Drug: Chidamide combined with cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chidamide combined with cisplatin
Study: NCT01464268
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of riboflavin every 2 minutes for the duration of UV exposure.
Study: NCT01464268
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of riboflavin every 1 minute for the duration of UV exposure.
Study: NCT01447888
Drug: 150% Oral Morphine Equivalent (OME)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
Study: NCT02414698
Drug: TESI
Normalized name: Mytesi
DrugBank: Tesidolumab (DB11926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural steroid injections given in the lumbar spine.
Study: NCT02781844
Drug: 25mcg rhPTH(1-84)
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.
Study: NCT02781844
Drug: 50mcg rhPTH(1-84)
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
Study: NCT02781844
Drug: 100mcg rhPTH(1-84)
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
Study: NCT01066156
Drug: Seroquel
Normalized name: Seroquel
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
Study: NCT01888562
Drug: Ponatinib
Normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
Study: NCT04331145
Drug: Ticagrelor 60mg
Normalized name: TICAGRELOR 60MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Platelet reactivity will be assessed by VerifyNow P2Y12 assay in ALL enrolled patients after confirmed use of clopidogrel for 4 days prior TAVI. Patients that have not completed a pre-treatment period of 4 days of clopidogrel will receive a loading dose of 300mg, according to the clinical practice, with assessment of platelet reactivity by VerifyNow P2Y12 at the following 6 hours. Based on results of basal VerifyNow P2Y12 assay at least 24 hours before the index-TAVI procedure, patients with:~High on-treatment platelet reactivity (PRU ≥ 160 assessed with VerifyNow P2Y12 assay): Patients will be switched to receive ticagrelor 60mg twice daily initiating at least 24hrs before TAVI procedure, in order to arrive to the index TAVI procedure with at least two doses of 60 mg, and will continue with Ticagrelor 60mg twice per day during the following three months.
Study: NCT02487732
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90mg twice daily for 5 weeks
Study: NCT02487732
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prasugrel 10mg once daily for 5 weeks
Study: NCT00140751
Drug: Lopinavir/ritonavir (drug)
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03010176
Drug: Ulevostinag
Normalized name: Ulevostinag
DrugBank: Ulevostinag (DB18789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT injection
Study: NCT03720873
Drug: erlotinib or gefitinib or icotinib
Normalized name: Medicated Pad or Tape
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
Study: NCT03720873
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with Anlotinib 12mg po d1-14 Q21d
Study: NCT03312283
Drug: lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
Study: NCT01383499
Drug: Tiotropium bromide
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhalation solution administered via Respimat in 3 different doses
Study: NCT01774487
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/kg/day divided in 3 doses, given orally for 90 days
Study: NCT02109315
Drug: Vitamine C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
Study: NCT02109315
Drug: Liraglutide 6 mg
Normalized name: liraglutide 6 MG/ML
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide endovenous de 0.6 mg. one time a day
Study: NCT01530451
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 120mg OD
Study: NCT03753659
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT03034538
Drug: Zonegran
Normalized name: Zonegran
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg
Study: NCT03034538
Drug: Zonegran
Normalized name: Zonegran
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg
Study: NCT00208780
Drug: Tetrahydrobiopterin
Normalized name: tetrahydrobiopterin
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03890120
Drug: Cilofexor
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet administered orally once daily
Study: NCT01628874
Drug: EMLA
Normalized name: EMLA
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
Study: NCT01628874
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
Study: NCT01080963
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
Study: NCT01080963
Drug: Cefuroxime
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
Study: NCT02387229
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg
Study: NCT01218893
Drug: Chloroquine prophylaxis
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
Study: NCT02240667
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg or 110 mg capsules twice daily
Study: NCT02270918
Drug: Kcentra
Normalized name: Kcentra
DrugBank: Prothrombin (DB11311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT02270918
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01882062
Drug: Triheptanoin 1g/kg/day
DrugBank: Triheptanoin (DB11677)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02418676
Drug: Gel with HPβCD-I complex
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation.
Study: NCT02418676
Drug: Gel with insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation.
Study: NCT02418676
Drug: Control gel
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation.
Study: NCT02354508
Drug: Pasireotide LAR
Normalized name: pasireotide LAR 20 MG Injection
DrugBank: Pasireotide (DB06663)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pasireotide 40 mg and 60 mg. Pasireotide 20 mg which was allowed for dose decrease in case of adverse event.
Study: NCT01465529
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% NaCl in water
Study: NCT01578772
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg tablets po daily for 6 weeks
Study: NCT02391337
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug intervention
Study: NCT02391337
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug intervention
Study: NCT02290132
Drug: Rabbit Anti-human Thymocyte Globulin (ATG)
Normalized name: Rabbit anti-human thymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
Study: NCT04303767
Drug: Casein phosphopeptide amorphous calcium phosphate
Normalized name: caseins
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: varnish containing calcium and phospate ions which act as a source for tooth remineralization
Study: NCT00461032
Drug: montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: montelukast 5 mg tablet Once a day (QD) for 8 weeks
Study: NCT01899248
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03422523
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous drip
Study: NCT03422523
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous drip/or Subcutaneous from cycle 2